Latest carfilzomib Stories
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
Maximum tolerated dose (MTD) identified and expansion cohort open to enrollment; Minimal Response (MR) or better has been observed in 25% of 8 patients treated to date at the MTD or higher
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
SAN FRANCISCO, Dec.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
- Final results from binimetinib Phase 2 in NRAS melanoma confirmed prior Progression Free Survival result and demonstrated encouraging Overall Survival- BOULDER, Colo., Nov.
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept.
- A political dynamiter.